Thieler Law Corp advises investors with losses exceeding $100,000 of the August 1, 2016 lead plaintiff deadline in a class action lawsuit filed against Eagle Pharmaceuticals Inc (NASDAQ:EGRX) (“Eagle Pharmaceuticals ” or “the Company”). The suit is pending in the U.S. District Court for the District of New Jersey and investors, who purchased Eagle Pharmaceuticals Inc securities between February 23, 2016 and March 18, 2016, have until August 1, 2016 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Eagle Pharmaceuticals Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:  the Company made misrepresentations about the FDA approval process for its new anticoagulant drug, KANGIO™.

On February 25, 2016, Eagle Pharmaceutical’s CEO stated, regarding the pending New Drug Application for KANGIO™, “We have been interacting with FDA and we are preparing for launch, everything seems to be on track for a March 19 approval, and we anticipate shipping in late Q1 or early Q2.”

On March 18, 2016, Eagle Pharmaceutical revealed that the FDA had issued a Complete Response Letter stating that it could not approve the drug application for KANGIO in its current form and requesting further characterization of bivalirudin-related substances in the drug.

On this news, the Company stock dropped $10.18 per share, or nearly 19%, to close at $43.50 per share on March 18, 2016.

If you were negatively impacted by your investment in Eagle Pharmaceuticals Inc securities between February 23, 2016 and March 18, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185